Back to top
more

Recordati Industria Chimica E Farmaceutica S.P.A. (RCDTF)

(Delayed Data from OTC)

$51.60 USD

51.60
NA

0.00 (0.00%)

Updated Jan 25, 2024 10:25 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RCDTF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Recordati Industria Chimica E Farmaceutica SPA falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents -99,999 325 303 8 222
Receivables NA 449 417 361 422
Notes Receivable NA 0 0 0 0
Inventories NA 447 271 287 254
Other Current Assets NA 16 15 12 9
Total Current Assets NA 1,237 1,006 883 906
Net Property & Equipment NA 168 155 152 149
Investments & Advances NA 30 40 52 43
Other Non-Current Assets NA 13 0 0 0
Deferred Charges NA 81 90 86 80
Intangibles NA 2,674 2,002 1,917 1,949
Deposits & Other Assets NA 10 39 8 18
Total Assets NA 4,213 3,332 3,098 3,146
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 88 10 14 15
Accounts Payable NA 237 211 151 197
Current Portion Long-Term Debt NA 307 264 309 168
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 35 35 34 24
Other Current Liabilities NA 306 222 153 254
Total Current Liabilities NA 973 741 661 657
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 177 32 47 48
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,413 900 889 1,050
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 20 25 43 48
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,584 1,697 1,640 1,803
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 28 31 30 29
Capital Surplus NA 88 99 96 94
Retained Earnings NA 1,935 1,966 1,720 1,533
Other Equity NA -264 -311 -288 -208
Treasury Stock NA 158 150 100 105
Total Shareholder's Equity NA 1,629 1,635 1,458 1,343
Total Liabilities & Shareholder's Equity NA 4,213 3,332 3,098 3,146
Total Common Equity 0 1,629 1,635 1,458 1,343
Shares Outstanding NA 206.30 206.30 NA 209.10
Book Value Per Share 0.00 7.90 7.92 -0.01 6.42

Fiscal Year End for Recordati Industria Chimica E Farmaceutica SPA falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 349 -99,999 266
Receivables NA NA 519 NA 524
Notes Receivable NA NA NA NA 0
Inventories NA NA 437 NA 459
Other Current Assets NA NA 26 NA 29
Total Current Assets NA NA 1,332 NA 1,279
Net Property & Equipment NA NA 188 NA 174
Investments & Advances NA NA 22 NA 26
Other Non-Current Assets NA NA NA NA 0
Deferred Charges NA NA 86 NA 82
Intangibles NA NA 2,959 NA 2,694
Deposits & Other Assets NA NA 19 NA 19
Total Assets NA NA 4,606 NA 4,274
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA 45 NA 25
Accounts Payable NA NA 275 NA 265
Current Portion Long-Term Debt NA NA 432 NA 315
Current Portion Capital Leases NA NA NA NA 0
Accrued Expenses NA NA NA NA 0
Income Taxes Payable NA NA 77 NA 59
Other Current Liabilities NA NA 211 NA 282
Total Current Liabilities NA NA 1,040 NA 946
Mortgages NA NA NA NA 0
Deferred Taxes/Income NA NA 168 NA 176
Convertible Debt NA NA NA NA 0
Long-Term Debt NA NA 1,499 NA 1,357
Non-Current Capital Leases NA NA NA NA 0
Other Non-Current Liabilities NA 21 NA 20
Minority Interest (Liabilities) NA NA NA NA 0
Total Liabilities NA NA 2,728 NA 2,498
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA NA 0
Common Stock (Par) NA NA 28 NA 28
Capital Surplus NA NA 91 NA 90
Retained Earnings NA NA 2,109 NA 2,119
Other Equity NA NA -213 NA -297
Treasury Stock NA NA 138 NA 164
Total Shareholder's Equity NA NA 1,878 NA 1,776
Total Liabilities & Shareholder's Equity NA NA 4,606 NA 4,274
Total Common Equity 0 0 101,877 0 1,776
Shares Outstanding NA NA NA NA 206.30
Book Value Per Share 0.00 0.00 -1.02 0.00 8.61